{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-22-000102","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2022-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.543760+00:00","generated_at":"2026-06-24T01:36:17.210563+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Xeris Biopharma Q2 net product revenue record $25.3M, reaffirms FY guidance","bullets":["Record Q2 net product revenue $25.3M, up 15% from Q1 and 34% pro forma YoY.","Gvoke net revenue $11.5M (+30% YoY); Keveyis $12.8M (+28% pro forma); Recorlev $1.0M.","Cash $111.6M at quarter-end; reaffirms FY net product revenue $105M-$120M, cash flow breakeven by end 2023.","Net loss $26.2M ($0.19/sh) in Q2, $59.9M ($0.44/sh) in H1.","Ogluo commercial partner Tetris Pharma acquired by Arecor Therapeutics in August 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-22-000102","json":"https://secwatch.observer/filing/0001867096-22-000102.json","markdown":"https://secwatch.observer/filing/0001867096-22-000102.md","text":"https://secwatch.observer/filing/0001867096-22-000102.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709622000102/0001867096-22-000102-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709622000102/xers-20220810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:36:17.210563+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}